Overview
Lumicitabine (ALS-8176) is an investigational nucleoside analog antiviral drug developed by Alios BioPharma, a subsidiary of Johnson & Johnson. It is designed to target respiratory syncytial virus (RSV), a common pathogen causing lower respiratory tract infections in infants, the elderly, and immunocompromised individuals. Lumicitabine functions as a prodrug, metabolizing into its active form to inhibit viral RNA polymerase, thereby preventing viral replication. Clinical trials have demonstrated its potential to reduce viral load and improve symptoms in RSV-infected patients. While not yet approved for commercial use, lumicitabine represents a promising candidate in the antiviral drug pipeline, addressing an unmet medical need for effective RSV therapeutics.
Physical and Chemical Properties
Lumicitabine is a white to off-white crystalline powder with a molecular weight of 407.83 g/mol. Its molecular formula is C₁₄H₁₈ClN₃O₇S, indicating the presence of chlorine, nitrogen, and sulfur atoms in its structure. The compound is soluble in water and dimethyl sulfoxide (DMSO), making it suitable for formulation in aqueous solutions for intravenous or oral administration. As a nucleoside analog, lumicitabine mimics natural nucleosides, allowing it to incorporate into viral RNA during replication. This incorporation disrupts the elongation of the RNA chain, leading to premature termination. The drug's stability under recommended storage conditions (-20°C, dry, dark environment) ensures its efficacy in research and potential clinical applications.
Main Applications
Lumicitabine is primarily investigated for the treatment of respiratory syncytial virus (RSV) infections, which are a leading cause of bronchiolitis and pneumonia in infants and severe respiratory illness in older adults. Its mechanism of action targets the viral RNA polymerase, a critical enzyme for RSV replication, offering a direct antiviral effect. In clinical settings, lumicitabine has shown promise in reducing viral load and alleviating symptoms in RSV-infected patients. Its development is particularly significant given the limited therapeutic options currently available for RSV. Beyond RSV, researchers are exploring its potential efficacy against other RNA viruses, though such applications remain experimental.
Safety and Storage
Lumicitabine should be handled with standard laboratory precautions to minimize exposure. Personal protective equipment (PPE), including gloves and safety goggles, is recommended when working with the compound. Avoid inhalation, ingestion, or direct skin contact, as its pharmacological activity may pose risks. For storage, lumicitabine must be kept at -20°C in a dry, dark environment to maintain stability. Prolonged exposure to light, moisture, or elevated temperatures can degrade the compound, reducing its efficacy. Proper labeling and secure storage are essential to prevent accidental misuse or contamination.
B2B Procurement Guide
Lumicitabine is available through specialized pharmaceutical chemical suppliers, often for research purposes only. B2B buyers should verify the supplier's credentials, ensuring compliance with Good Manufacturing Practices (GMP) and relevant regulatory standards. Pricing is typically provided upon request, as it varies based on quantity and purity requirements. Procurement teams should confirm the compound's Certificate of Analysis (CoA) to guarantee quality and purity. Additionally, buyers must ensure compliance with local import/export regulations, particularly for investigational drugs. Establishing long-term relationships with reputable suppliers can facilitate consistent access to lumicitabine for ongoing research or clinical development.
Related Manufacturers
- 主营：小分子现货、科研小分子、单抗、Lumicitabine、多肽、RAS抑制剂、中间体、医药中间体、实验室用试剂、实验小分子、氯苯甲酸、咪唑乙醇、氧代丙腈、贝达喹啉、贝伐单抗、谷氨酰胺、喹啉-21氢、决明内酯、溴喹唑啉、苯基丙基、乙基己基